Abstract
Introduction: Tranexamic acid, an anti-fibrinolytic agent, has been used in the treatment of melasma, a hyperpigmentary condition that causes dark patches on the skin. Its effectiveness in melasma is related to the inhibition of plasminogen activation, a protein involved in the formation of melanin. Objective: to analyze the effects of tranexamic acid in the treatment of melasma. Methods: It consists of an integrative review carried out through the Scopus, PubMed® and SciELO databases, using the descriptors tranexamic acid, safety and melasma. Studies published in the last 12 years, in English, Spanish or Portuguese, that addressed the topic were included. Results and discussions: TXA combined with different therapies, especially lasers, is effective and safe in the treatment of melasma, showing better results than monotherapy. Intradermal administration of TXA often results in better clinical outcomes compared to the topical form. Considerations: It is concluded that TXA offers an effective and safe option for the treatment of melasma, highlighting its potential as a valuable tool in the therapeutic arsenal against melasma.
References
BADRAN, A. Y.; ALI, A. U.; GOMAA, A. S. Efficacy of topical versus intradermal injection of tranexamic acid in Egyptian melasma patients: A randomised clinical trial. Australasian Journal of Dermatology, v. 62, n. 3, p. e373-e379, ago. 2021.
BAGHERANI, N. The efficacy of tranexamic acid in the treatment of melasma. Dermatologic Therapy, v. 28, n. 4, p. 265, 2015.
BALKRISHNAN, R. et al. Improved quality of life with effective treatment of facial melasma: the Pigment Trial. Journal of Drugs in Dermatology, v. 3, n. 4, p. 377–381, 2004.
BEHRANGI, E. et al. Comparison of efficacy and safety of tranexamic acid mesotherapy versus oral tranexamic acid in patients with melasma undergoing Q-switched fractional 1064-laser: A blinded RCT and follow-up. Journal of Cosmetic Dermatology, v. 21, n. 1, p. 279-289, jan. 2022.
GAMEA, M. M. et al. Comparative study between topical tranexamic acid alone versus its combination with autologous platelet rich plasma for treatment of melasma. Journal of Dermatological Treatment, v. 33, n. 2, p. 798-804, mar. 2022.
GRIMES, P. E. Management of hyperpigmentation in darker racial ethnic groups. Seminars in Cutaneous Medicine and Surgery, v. 28, p. 77-85, 2009.
KIM, H. J. et al. Efficacy and safety of tranexamic acid in melasma: A meta-analysis and systematic review. Acta Dermato-Venereologica, v. 97, n. 7, p. 776–781, 2017.
LI, D. et al. Tranexamic acid can treat ultraviolet radiation-induced pigmentation in guinea pigs. European Journal of Dermatology, v. 20, p. 289-292, 2010.
LI, Y. et al. Efficacy and safety of 755-nm picosecond alexandrite laser with topical tranexamic acid versus laser monotherapy for melasma and facial rejuvenation: a multicenter, randomized, double-blinded, split-face study in Chinese patients. Lasers in Medical Science, v. 37, n. 7, p. 2879-2887, set. 2022.
MAEDA, K.; TOMITA, Y. Mechanism of the inhibitory effect of tranexamic acid on melanogenesis in cultured human melanocytes in the presence of keratinocyte-conditioned medium. Journal of Health Science, v. 53, p. 389-396, 2007.
NA, J. I. et al. Effect of tranexamic acid on melasma: a clinical trial with histological evaluation. Journal of the European Academy of Dermatology and Venereology, v. 27, n. 8, p. 1035-1039, ago. 2013.
PANDYA, A. G. et al. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. Journal of the American Academy of Dermatology, v. 64, n. 1, p. 78–e2, 2011.
QU, Y. et al. Clinical observation and dermoscopy evaluation of fractional CO2 laser combined with topical tranexamic acid in melasma treatments. Journal of Cosmetic Dermatology, v. 20, n. 4, p. 1110-1116, abr. 2021.
ROBERTS, I. Tranexamic acid in trauma: how should we use it? Journal of Thrombosis and Haemostasis, v. 13, p. S195–S199, 2015.
RODRIGUES, M.; PANDYA, A. G. Melasma: Clinical diagnosis and management options. Australasian Journal of Dermatology, v. 56, p. 151-163, 2015.
SAKI, N.; DARAYESH, M.; HEIRAN, A. Comparing the efficacy of topical hydroquinone 2% versus intradermal tranexamic acid microinjections in treating melasma: a split-face controlled trial. Journal of Dermatological Treatment, v. 29, n. 4, p. 405-410, jun. 2018.
SHANKAR, K. et al. Evidence-based treatment for melasma: Expert opinion and a review. Dermatology Therapy (Heidelberg), v. 4, p. 165-186, 2014.
SHIHAB, N. et al. Randomised, controlled, double-blind study of combination therapy of oral tranexamic acid and topical hydroquinone in the treatment of melasma. Australasian Journal of Dermatology, v. 61, n. 3, p. 237-242, ago. 2020.
TARAZ, M.; NIKNAM, S.; EHSANI, A. H. Tranexamic acid in treatment of melasma: a comprehensive review of clinical studies. Dermatology Therapy, v. 30, n. 3, 2017.
TSE, T. W.; HUI, E. Tranexamic acid: An important adjuvant in the treatment of melasma. Journal of Cosmetic Dermatology, v. 12, n. 1, p. 57–66, 2013.
XU, Y. et al. Efficacy of functional microarray of microneedles combined with topical tranexamic acid for melasma. Medicine (United States), v. 96, n. 19, 2017.
YALAMANCHILI, R.; SHASTRY, V.; BETKERUR, J. Clinicoepidemiological study and quality of life assessment in melasma. Indian Journal of Dermatology, v. 60, n. 5, p. 519, 2015.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Carolline Vaz, Júlia Leandra Fernandes, Isadora Alves de Andrade, Pierre Rodrigues Bernardino, Victor Hugo Mundim Melo, Ana Carolina Benaventana de Padua Carneiro, Alex Italo da Silveira Sales, Gabrielly Alves Trigo, Rodrigo Cordon Isaac, Jheniffer da Silva Oliveira, Thomas de Matos Soares, Giovana Menezes, Allycia Jamylle Nogueira de Mello, Maria Luiza Normande Guido Santos, Mariana Alencar Máximo Lacerda, Marina Lins Tavares Pedroza Monteiro, Maria Karoline Gomes da Silva, Brunna Karolyne Aguiar Ferreira, Lucélia Barros Tenório, Bruna Michelly de Barros Canuto Pinheiro, Bruna Tavares Oliveira